41
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Iatrogenic Kaposi's sarcoma caused by corticosteroids

      letter

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To the Editor, Kaposi´s sarcoma (KS) is a malignant neoplasm of endothelial cells with low proliferation, described by Moritz Kaposi in 1872. It is classified into four groups: endemic, reported in African regions; epidemic, which is acquired immune deficiency syndrome(AIDS)-related; classic, at first reported primarily in Ashkenazi Jews and Mediterranean peoples, indicating a genetic relationship; and iatrogenic, which affects immunosuppressed patients of autoimmune and malignant diseases, and transplanted recipients. A 36-year-old female patient was diagnosed with lepromatous leprosy in 2008. After a five-month multibacillary treatment (dapsone, rifampicin and clofazimine), erythematous and painful nodules disseminated throughout her body. Type 2 reaction was diagnosed and treated with prednisone 40 mg/day, ranging from 20-60 mg/day according to the patient's response. Treatment lasted between 2008 and 2013 due to persistent lesions. However, a new exam in 2013 showed violaceous and erythematous nodules and plaques, ranging from 1.0-10cm, distributed on the upper and lower limbs, pubis, and left breast. Non-depressible edema was also found on the lower limbs (Figure 1). No lesions were found on oral and genital mucosae. Figure 1 Violaceous and erythematous papules and plaques with irregular and well-defined edges, and smooth and bright surface on the upper and lower limbs The lesion was asymptomatic, and the patient showed no improvement, despite the continued use of high doses of prednisone. SK was considered and confirmed after an anatomopathological examination (Figure 2A). Immunohistochemistry for human herpesvirus-8 (HHV-8) was positive (Figure 2B). Figure 2 A: Proliferation of fusiform cells, band-forming cells with nuclear atypia and mitotic activity, and extravasation of lymphocytes in the dermis (40x H&E). B: Immunohistochemistry positive for human herpesvirus-8 (HHV-8) Blood count, liver and kidney exams, serological tests for syphilis, hepatitis B and C and HIV, chest X-ray, and abdominal ultrasound were normal or non-reactive. The lesion was diagnosed as iatrogenic KS induced by prolonged use of corticosteroids (CS). As a critical therapeutic measure, due to the large number of lesions on different parts of the body, the patient had to stop taking the inducing medication. CS dose was gradually reduced, but the patient showed new erythematous and painful nodules on her upper and lower limbs, accompanied by malaise. It was interpreted as type 2 reaction; clofazimine 300 mg/day was prescribed for 30 days to control the reaction, with gradual dose reduction and the previous slow withdrawal of CS. After three months, the lesions of type 2 reaction disappeared. The medication was fully withdrawn; six months after the KS diagnosis, these lesions improved with residual brownish stain (Figure 3). A three-year follow-up showed persisting residual lesions. Figure 3 Residual brownish macules on the upper and lower limbs KS in immunosuppressed patients was first reported in transplant recipients under cyclosporine. However, it has also been reported in other haematological, rheumatological, and pulmonary diseases caused by immunosuppressive treatment. 1 This CS-related disease was found in the treatment of different diseases, such as idiopathic thrombocytopenic purpura, temporal arteritis, Sjogren's syndrome, pemphigus vulgaris, bullous pemphigoid, dermatomyositis, systemic lupus erythematosus, primary biliary cirrhosis, rheumatoid arthritis, and lymphoproliferative disorders. 1,2 This case reports a patient under treatment of leprosy type 2 reaction. The patient's medical records failed to reveal the time between the beginning of the CS treatment and the emergence of the first KS lesions. In the reviewed literature, the KS may appear between one month and 20 years after the immunosuppressive drug is introduced. 2 The presence of HHV-8 was first associated with the KS in 1994. The herpesvirus DNA sequence was identified in KS fragments from patients with AIDS 3 and has subsequently been reported in all KS types. It infects the endothelial cells and remains there in a latent state. When reactivated, it causes aberrant angiogenesis, which is an increase in production and secretion of pro-angiogenic factors. 4 KS clinical lesions may vary from brownish macules and plaques to violaceous exophytic tumors. Some lesions may ulcerate or invade surrounding tissues, such as the bones. Different stages may coexist, as seen in this case report, but adjacent tissues and inner organs remain intact. 5 The severe lesions and the different body regions affected required the withdrawal of the immunosuppressive drug prescribed in the earlier therapy. Such measured has been reported by other authors and was successfully reproduced in this case. 2 KS is a HHV-8-associated tumor and must be taken into account for all cases of patients undergoing immunosuppresseve therapy, regardless of the drug used. As far as it could be assessed, this is the first case report of KS in immunosuppressed patients by CS during leprosy reaction treatment.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: found
          • Article: not found

          Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.

          Representational difference analysis was used to isolate unique sequences present in more than 90 percent of Kaposi's sarcoma (KS) tissues obtained from patients with acquired immunodeficiency syndrome (AIDS). These sequences were not present in tissue DNA from non-AIDS patients, but were present in 15 percent of non-KS tissue DNA samples from AIDS patients. The sequences are homologous to, but distinct from, capsid and tegument protein genes of the Gammaherpesvirinae, herpesvirus saimiri and Epstein-Barr virus. These KS-associated herpesvirus-like (KSHV) sequences appear to define a new human herpesvirus.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Kaposi sarcoma.

            Kaposi sarcoma (KS) is a low-grade vascular tumor associated with Kaposi sarcoma herpesvirus/human herpesvirus 8 (KSHV/HHV8) infection. Kaposi sarcoma lesions predominantly present at mucocutaneous sites, but may involve all organs and anatomic locations. Recognized epidemiologic-clinical forms of KS include classic, African (endemic), AIDS-associated (epidemic), and iatrogenic KS. New clinical manifestations have been described, such as antiretroviral therapy-related KS regression or flares. Kaposi sarcoma lesions evolve from early (patch stage) macules into plaques (plaque stage) that grow into larger nodules (tumor stage). Newer histologic variants include anaplastic, hyperkeratotic, lymphangioma-like, bullous, telangiectatic, ecchymotic, keloidal, pyogenic granuloma-like, micronodular, intravascular, glomeruloid and pigmented KS, as well as KS with sarcoidlike granulomas and KS with myoid nodules. Latency-associated nuclear antigen (HHV8) is the most specific immunohistochemical marker available to help distinguish KS from its mimics. Since KS remains one of the most common AIDS-defining malignancies, it is important that pathologists be able to recognize KS and its contemporary manifestations.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The appearance of Kaposi sarcoma during corticosteroid therapy.

              Four epidemiologic types of Kaposi sarcoma (KS) are known: classic KS, endemic African KS, epidemic or acquired immunodeficiency syndrome-related KS, and KS associated with immunosuppressive therapy. In most of the latter patients, KS was reported to have developed after organ transplantation, particularly renal transplantation. Thirty-nine patients who have not had a transplant have been reported to have KS associated with corticosteroid therapy. The authors studied 10 patients with the appearance of KS during corticosteroid therapy (6 men, 4 women; age range, 42-79 years) who were treated with corticosteroids for autoimmune disorders (5 patients), lymphoproliferative disorders (2 patients), and diseases unrelated to the immune system (3 patients). Genetically programmed susceptibility to corticosteroid-related KS was suggested by the descent of the study patients as well as most of those reported previously. The prognosis was guarded in all the study patients. Corticosteroids should be withdrawn to achieve clinical remission.
                Bookmark

                Author and article information

                Contributors
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Journal
                abd
                Anais Brasileiros de Dermatologia
                An. Bras. Dermatol.
                Sociedade Brasileira de Dermatologia (Rio de Janeiro, RJ, Brazil )
                0365-0596
                1806-4841
                December 2016
                : 91
                : 6
                : 867-869
                Affiliations
                [1] São Paulo São Paulo orgnameIrmandade da Santa Casa de Misericórdia de São Paulo Brazil
                Article
                S0365-05962016000600867
                10.1590/abd1806-4841.20165772
                ad1792e4-c8d2-4741-9f28-75a60def6588

                This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

                History
                : 13 June 2016
                : 07 March 2016
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 5, Pages: 3
                Product

                SciELO Brazil


                Comments

                Comment on this article